RVNC - Revance Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue3,729262300300
Cost of Revenue----
Gross Profit3,729262300300
Operating Expenses
Research Development87,00075,06145,08142,229
Selling General and Administrative59,36342,69834,37530,388
Non Recurring----
Total Operating Expenses146,363117,75979,45672,617
Operating Income or Loss-142,634-117,497-79,156-72,317
Income from Continuing Operations
Total Other Income/Expenses Net3,066-3,090-10,114-1,159
Earnings Before Interest and Taxes-142,634-117,497-79,156-72,317
Interest Expense-44-457-1,082-1,190
Income Before Tax-139,568-120,587-89,270-73,476
Income Tax Expense3,000---
Minority Interest----
Net Income From Continuing Ops-142,568-120,587-89,270-73,476
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-142,568-120,587-89,270-73,476
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-142,568-120,587-89,270-73,476